Lytenava (bevacizumab-vikg)

Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Average sales price and wholesale acquisition cost
Published: 2026-09-28T12:24:10-04:00

Neovascular age-related macular degeneration

Manufacturer: Outlook Therapeutics
Regulatory submission: BLA approved July 2026
Launch: Anticipated before the end of 2026
Last updated: September 28, 2026

Section

Product information and disease description Product description Product information

Average sales price and wholesale acquisition cost

1 evidence topic · 1 source

Wholesale acquisition cost

“On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial.” (opens the source at this quote in a new tab)

Average sales price

No evidence found.